Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — H1 2018 Earnings Presentation

76 slides from Aspen Pharmacare's earnings presentation, Mar 8, 2018

  1. Slide 1: Interim Results Presentation

    Interim Results Presentation For the six months ended 31 December 2017

  2. Slide 2: Table of Contents

    TABLE OF CONTENTS Stephen Saad Group Chief Executive Aspen’s 20 Year History Unpacking Aspen H1 2018 Performance Review Gus Attridge Deputy Group Chief Executive Financial Review Stephen Saad Summary & Prospects Appendices

  3. Slide 3: Financial Highlights

    FINANCIAL HIGHLIGHTS 3 Strong H1 performance  Revenue at ZAR 21.9bn − Revenue momentum sustained from H2 2017  EBITDA at ZAR 6.3bn − EBITDA growth above revenue growth − Operating profit to cash flow conversion rate 78%  Forecast at 100% for the year Growth CER Growth  NHEPS (cents) vs prior yea

  4. Slide 4: Group Revenue

    GROUP REVENUE 4 R’million H1 2018 H1 2017 % change H1 2017 (CER)* % change Commercial Pharma 17 121 14 997 14% 14 893 15% Anaesthetics 4 409 2 817 57% 2 766 59% Thrombosis 3 276 2 729 20% 2 793 17% High Potency & Cytotoxics 2 193 2 417 -9% 2 383 -8% Regional Brands 7 243 7 035 3% 6 951 4% Nutritiona

  5. Slide 5: Aspen's 20-year history

    Hot DING Ss Aspen’s 20-year history

  6. Slide 6: Celebrating 20 Years | 1999 - 2018

    CELEBRATING 20 YEARS | 1999 - 2018 6 FY1999 – FY2013 FY2014 – H1 2018 (annualised) From humble beginnings to regional leadership From regional leadership to global therapeutic leadership annualised Going for 20th year of unbroken NHEPS growth

  7. Slide 7: FY 1999 – FY 2013

    FY 1999 – FY 2013 7 FY 1999 Sales: ZAR 0.5bn FY 2013 Sales: ZAR 19.3bn SA & Australia = 73% Rest of World • No 1 in SA ~ 1 in 4 scripts 27% South Africa dispensed 36% • No 1 in Australia ~ 1 in 5 scripts written Australasia 37% South Africa only From humble beginnings in Durban to regional leadershi

  8. Slide 8: Regional Learning Defines Global Strategy

    REGIONAL LEARNING DEFINES GLOBAL STRATEGY 8  Strategic review of our strengths & weaknesses in 2013  Returns from scale, sales and supply chain − Risk of commoditisation of generics − Critical mass gives returns − Funding required for patents − Global strategy formulated − Fifteen years taken to b

  9. Slide 9: FY 2013 – H1 2018 (Annualised)

    FY 2013 – H1 2018 (ANNUALISED) 9 FY 2013 Sales: ZAR 19.3bn H1 2018 (annualised) Sales : ZAR 43.8bn SA & Australia = 73% SA & Australia = 35%* South Africa Rest of • No.1 in Anaesthetics globally (ex-USA) 20% World South Africa • No.2 in injectable Anticoagulants 27% 36% globally (ex-USA) Australasia

  10. Slide 10: Unpacking Aspen

    Unpacking Aspen FY 2013 – H1 2018

  11. Slide 11: Debt & Assets

    DEBT & ASSETS 11  Debt − Net borrowings ↑ ZAR 32.0bn since FY 2013 67.3  Assets − Significant increase in balance sheet values  Intangibles ↑ ZAR 48.4bn 43.1  PPE ↑ ZAR 5.8bn  Applied to Working Capital ↑ ZAR 12.4bn 18.9 17.8 11.1 5.4 FY 2013 H1 2018 Net borrowings (ZAR'bn) Intangible Assets (Z

  12. Slide 12: Intangible Assets & Goodwill

    INTANGIBLE ASSETS & GOODWILL 12 High Potency & Regional Brands Therapeutic class Anaesthetics Thrombosis Other Cytotoxic South Africa Australia Sales Multiple 2.6 2.1 2.8 0.4 1.9 0.9 23.0 14.0 14.6 13.0 12.1 8.8 6.6 6.9 4.4 5.8 3.6 2.1 Anaesthetics Thrombosis High Potency and South Africa - Australi

  13. Slide 13: Amortisation of Intangibles

    AMORTISATION OF INTANGIBLES 13  Amortisation treatment differs between generics,  Useful life assessed against, inter alia patents and brands − Historic & budgeted sales − Aspen has mainly indefinite life intangibles − Investment plans & willingness to commit resources  Means the values are teste

  14. Slide 14: Investment in Capex & Working Capital

    INVESTMENT IN CAPEX & WORKING CAPITAL 14  Capex investments critical − Security of supply − Global advantage  Economies of scale  Lower COGS, higher quality  Sustainability of entire business model  Capex projects are long term  All capex approved with a commercial return  Working Capital +ZA

  15. Slide 15: Quality of Earnings

    QUALITY OF EARNINGS 15  We validate quality of earnings by comparing Operating cash flow per share vs Operating income per share  We have a successful 20 year history on this metric  Cash is King − Cuts through all accounting nuances  Cash then applied to − Capex, acquisitions & dividends  We h

  16. Slide 16: Our Current GPS

    OUR CURRENT GPS 16  Aspen has globalised  Leading global and regional positions  Substantial acquisitions have been settled − No 1 in anaesthetics (excluding USA)  Enhanced capability and capacity − No 2 in injectable anticoagulants (excluding USA) − Globally valuable IP − Differentiated and com

  17. Slide 17: Our Current GPS (Continued)

    OUR CURRENT GPS (CONTINUED) 17  Over the last 12 months  Acquisitions in pharma are expensive − ↑ Margins − Acquisitive only financiers in pharma and other industries have often failed − ↑ EBITDA > ↑ Sales  In spite of heavy equity funding  Accelerating EBITDA margin  Aspen has also grown inorg

  18. Slide 18: What Is the Bottom Line? FY 2013 – H1 2018

    WHAT IS THE BOTTOM LINE? | FY 2013 – H1 2018 (ANNUALISED) 18  Aspen has not only diversified into a global multinational − More than doubled revenue − Without diluting EBITDA margins  Extent of the successful metamorphosis is best measured by Operating profit +105% NHEPS +108% New shares issued NI

  19. Slide 19: H1 2018 Performance Review

    Hot DING Ss H1 2018 Performance Review

  20. Slide 20: Commercial Pharma Revenue Contribution by Region & Therapeutic Category

    COMMERCIAL PHARMA REVENUE CONTRIBUTION | BY REGION & THERAPEUTIC CATEGORY 20 Total Commercial Pharma Revenue +15% ZAR17.1 bn 54% -27% EM revenue Latam ROW contribution +6% ZAR 1.0bn +59% Developing +22% Europe & CIS 6% Asia Pacific Anaesthetics SSA Emerging ZAR 2.3bn Markets 13% ZAR 4.4bn China 26%

  21. Slide 21: Anaesthetic Brands

    ANAESTHETIC BRANDS 21 Regional representation R’million H1 2018 H1 2017 % change (CER) 46% Developed Markets 2 374 1 561 52% Latam EM revenue China Contribution Emerging Markets 2 035 1 205 69% +69% Emerging Total Revenue 4 409 2 766 59% Markets  Largest area of focused brands MENA North − Base eff

  22. Slide 22: Anaesthetic Brands

    ANAESTHETIC BRANDS 22  China’s return to growth sustained − Diprivan +7% vs -19.7% in Dec 2015 − Naropin +1% in Dec 2015  +20% before supply impact  -23% after supply impact  Brazil overperforming in Latam  Future sustainable supply through Aspen sites − Well positioned to compete globally  Gl

  23. Slide 23: Thrombosis Brands

    THROMBOSIS BRANDS 23 R’million H1 2018 H1 2017 % change Regional representation (CER) Developing 44% Developed Markets 1 841 1 675 10% Europe & CIS EM revenue Emerging Markets 1 435 1 118 28% Contribution +28% Total Revenue 3 276 2 793 17% Emerging China Markets  Developed EU +11% MENA, Latam& SSA

  24. Slide 24: High Potency & Cytotoxic Brands

    HIGH POTENCY & CYTOTOXIC BRANDS 24 R’million H1 2018 H1 2017 % change Regional representation (CER) Developed Markets 1 294 1 459 -11% Developing 41% Latam Europe & CIS EM revenue Emerging Markets 899 924 -3% contribution Total Revenue 2 193 2 383 -8% Emerging -3% Markets Asia North  Decline exclus

  25. Slide 25: Regional Brands

    REGIONAL BRANDS 25 Regional representation R’million H1 2018 H1 2017 % change (CER) SSA 67% SSA 3 868 3 298 17% EM revenue Asia Pacific 2 293 2 170 6% contribution +13% Latam 614 590 4% Emerging Rest of World 468 893 -48% Markets Total Revenue 7 243 6 951 4%  Excluding HPC, category grew +10% − Imp

  26. Slide 26: Regional Brands | SSA

    REGIONAL BRANDS | SSA 26 R’million H1 2018 H1 2017 % change  Private Sector +14% − Aspen has largest share in Private Sector Total SA Revenue 3 480 2 870 21%  No 1 brand  4 of the top 10 brands Private sector 2 500 2 186 14%  5 of the top 15 generics - OTC 827 598 38%  Prescription +5% - Prescr

  27. Slide 27: Regional Brands | Asia Pacific

    REGIONAL BRANDS | ASIA PACIFIC 27 R’million H1 2018 H1 2017 % change (CER) Total Australasia Revenue 1 958 1 912 2% OTC 443 413 7% Prescription 1 515 1 499 1% Total Asia Revenue 335 258 30% Total Asia Pacific Revenue 2 293 2 170 6%  Australasia ̶ OTC +7%  Robust performance of new molecules launch

  28. Slide 28: Commercial Pharma | Prospects

    COMMERCIAL PHARMA | PROSPECTS 28  Anaesthetics synergistic  Operational performance areas to include − Fit for existing infrastructures − Focus Brands − Consistent global supply  Anaesthetics - supply management  Strategic advantage  Thrombosis - maintain current momentum  Complexity of manufa

  29. Slide 29: Nutritionals

    NUTRITIONALS 29 R’million H1 2018 H1 2017 % change (CER) Latin America 658 704 -7% SSA 497 490 1% Asia Pacific 455 428 6% Total Revenue 1 610 1 622 -1%  Latam  Asia Pacific − Positive growth in Infacare in Mexico medium-price segment − Market now stabilised  Offset by “Breastfeeding is Best” camp

  30. Slide 30: Operations

    OPERATIONS 30 R’million H1 2018 H1 2017 % change (CER) API 2 297 2 164 6% FDF 896 1 072 -16% Total Revenue 3 193 3 236 -1%  Strong API performance continues  Manufacturing facilities being reshaped − Both FCC & Oss − Oss end-state by June 2018 − Demonstration of capability  FDF affected by − Prou

  31. Slide 31: Financial review

    Hot DING Ss Financial review

  32. Slide 32: Financial Performance Headlines

    FINANCIAL PERFORMANCE HEADLINES 32 Acquisitive and organic Improved margin % Lower revenue growth Finance charges Benefit of second transaction Currency influence: Capex spend realignment with Astra Zeneca neutral below plan Working capital Cash Flows Leverage ratio stable on track comfortable

  33. Slide 33: Abridged Statement of Normalised Comprehensive Income

    ABRIDGED STATEMENT OF NORMALISED COMPREHENSIVE INCOME 33 R ’million H1 2018 H1 2017 % change H1 2017 % change (CER) Net revenue 21 924 19 822 11% 19 751 11% Cost of sales (10 747) (10 259) 5% (10 131) 6% Gross profit 11 177 9 563 17% 9 620 16% Gross profit margin 51% 48% 49% EBITDA 6 306 5 499 15% 5

  34. Slide 34: Currency Impact | H1 2018

    CURRENCY IMPACT | H1 2018 34 26% Revenue 23% 20% Reported CER 14% Revenue +11% +11% 7% Normalised EBITDA +15% +13% 5% 5% NHEPS +26% +25% EUR ZAR AUD USD JPY CNY Other  Most relevant currencies affecting earnings − EUR, ZAR, AUD − CNY, JPY − USD  Maintenance of stronger ZAR will be unfavourable to

  35. Slide 35: EBITDA Margin

    EBITDA MARGIN 35 Contribution to change in Normalised EBITDA Margin +1.1% -2.9% -1.4% -0.2% 5.9% -1.4% -1.0% -0.3% -0.4% 28.8% 27.7% Gross profit +2.8% -0.9% Net opex -1.7% H1 2017 Therapeutic Regional Brands Nutritionals Selling & Administrative Net other H1 2018 Normalised focused brands Distribut

  36. Slide 36: Reconciliation of NHEPS

    RECONCILIATION OF NHEPS 36 Cents H1 2018 H1 2017 % change Basic earnings per share (EPS) 806.0 618.6 30% Profit on sale of property, plant and equipment 0.2 0.5 -64% Net impairment of property, plant and equipment 2.5 0.3 >100% Impairment of intangible assets 33.1 8.5 >100% Loss on sale of intangibl

  37. Slide 37: Net Funding Costs

    NET FUNDING COSTS 37 R’million H1 2018 H1 2017 % change Net interest paid (734) (771) -5% Foreign exchange gains /(losses) 140 (52) > 100% Forward exchange contracts losses (90) (101) -11% Notional interest on financial instruments (136) (155) -12% Normalised net funding costs (820) (1,079) -24% Deb

  38. Slide 38: Intangible Assets

    INTANGIBLE ASSETS 38 R’million H1 2018 FY 2017 Net book value 67 326 60 006  Indefinite period useful life intangible assets first recognised in FY 2009 – after initial global brands acquisition − Accounting treatment very similar to goodwill  Per IAS 38, an indefinite period useful life intangibl

  39. Slide 39: Intangible Assets | Product Life Cycle

    INTANGIBLE ASSETS | PRODUCT LIFE CYCLE 39 Patent-protected Post- patent expiry SALES VALUE ASPEN ACQUIRES LAUNCH YEARS

  40. Slide 40: Intangible Assets (Continued)

    INTANGIBLE ASSETS (CONTINUED) 40  Aspen’s business model is based upon building a product portfolio generating sustainable, predictable cash flows − Not patent protection dependant − Not a first-to-launch generic play  Approximately ZAR 2.5bn in profits has been realised on the sales of businesses

  41. Slide 41: Intangible Assets (Continued)

    INTANGIBLE ASSETS (CONTINUED) 41  Contextualisation of indefinite period useful life recognition − Compliant with International Accounting Standards − FY 2018 is the tenth year of continuous application by Aspen − Rigorous annual impairment testing is performed − Does not result in over-valuation o

  42. Slide 42: Effective Tax Rate

    EFFECTIVE TAX RATE 42 H1 2018 H1 2017 FY 2017  Aspen’s effective tax rate is the product of the mix of underlying tax rates of countries in which the Group generates Unadjusted 18.1% 18.1% 18.0% its income − Mix is variable, influenced by performance and evolution of Normalised 17.6% 16.8% 17.1% pr

  43. Slide 43: Effective Tax Rate (Continued)

    EFFECTIVE TAX RATE (CONTINUED) 43  Aspen does not pursue aggressive tax structures − No off-balance sheet financing − No trusts and similar look-through structures  Aspen seeks to be fully compliant with OECD transfer pricing principles and in-country tax legislation − Allocation of earnings throu

  44. Slide 44: PPE Capital Expenditure

    PPE CAPITAL EXPENDITURE 44  Major projects underway to enable Aspen to manufacture Anaesthetics PPE Capex - ZAR'million − Port Elizabeth - steriles 2 500 2 400 − Notre Dame de Bondeville – blow-fill seal 2 000 H2 − Bad Oldesloe – creams, gels, liquids 1 580 1 500 1 000 1 593 1 741 1 329 1 484 500 8

  45. Slide 45: Cash Flows

    CASH FLOWS 45 R’million H1 2018 H1 2017 Operating Cash Flow - R’million H1 2018 Net Working capital 17 793 16 635 Net Working capital – excluding Oss 13 413 12 375 Working capital as % of revenue 41% 42% 6 145 -1 013 -607 -1 523 Less: Attributable to Oss -7% -8% 3 002 Working capital excluding Oss a

  46. Slide 46: Borrowings

    BORROWINGS 46 R’million H1 2018 H1 2017 Blended interest rates for borrowings Opening balance 37 131 32 694 Debt denomination H1 2018 Weighted average rate p.a (NACQ) Cash flow from operating activities (3 002) (3 232) as at 31 December 2017 Capital expenditure 820 736 ZAR 8.60% AUD 3.82% Proceeds f

  47. Slide 47: Borrowings

    BORROWINGS 47 Net Debt: R43.1 billion Analysis of ZAR43.1 billion net borrowings 35.6 Net borrowings 43.1 South Africa 9.5 Cash ZAR 8.5 22% H1 2017 Asia Pacific 9.4 H1 2018 AUD Current 22.0 5% International EUR 35.6 Non-current 73% 29.6 0.0 10.0 20.0 30.0 40.0 50.0  Amend and extend exercise planne

  48. Slide 48: Summary & prospects

    Hot DING Ss Summary & prospects

  49. Slide 49: Pipeline

    PIPELINE 49  Pipeline – Focus Brands − Thrombosis – geographic expansion of Orgaran − Anaesthetics  Additional European territories submitted  existing products  USA reactivation submission June 2018  Enabled by lower COGS  Clinical trials for HIT indication  existing products, new markets 

  50. Slide 50: Synergies

    SYNERGIES 50  Key operational synergies include, inter alia − Capacity reshape and volume growth in NDB facility − Bringing Mono-Embolex into Aspen supply chain − Restructuring Oss facilities and outsourcing intermediates − Fixing Danaparoid and Estrogens  Commercial synergies could include  HPC

  51. Slide 51: Nutritionals | Globally

    NUTRITIONALS | GLOBALLY 51  We are reviewing our strategic options for infant formula  Aspen has a strong market position in key geographies − Asia Pacific: No 2 in Australia − South Africa: No 2 in SA − Latam: Top 4/5 in most markets  Key growth opportunities − Registration in China  Estimated

  52. Slide 52: Nutritionals | China Strategy

    NUTRITIONALS | CHINA STRATEGY 52  Registration in January 2018  E-commerce − Ahead of March date − 18.3% market share  ±2000 brands currently − Highest growth rate +19% − Could fall to 500 − JD.com, Taobao, DanDan and Amazon  Focus on two routes-to-consumer  Expanding to Sunning and others − E-

  53. Slide 53: Regulatory Challenges

    REGULATORY CHALLENGES 53  Addressed major EHS challenges at Oss − Real threat of closure  Environmental – remediation project agreed − All leakage repaired  Health & Safety – addressed fire, hazardous materials and personal protection − Resolved through safe storage locations − Process and rebuil

  54. Slide 54: Commercial Pharma | Geographic Overview

    COMMERCIAL PHARMA | GEOGRAPHIC OVERVIEW 54  Asia Pacific  Europe CIS − Asia Pacific now 33% of total Commercial Pharma revenue − Sustain momentum change in Thrombosis momentum − 3 of top 5 sales countries are in Asia Pacific region  Latam − Asia > Australia − Brazil settled and performing  4 yea

  55. Slide 55: Commercial Pharma | Growth Highlights

    COMMERCIAL PHARMA | GROWTH HIGHLIGHTS 55 Total Commercial Pharma +15% DM +7% EM +22% Focus Brands +24% DM +17% EM +35% Focus Brands +6% DM +0% EM +14% excl. Anaesthetics Regional Brands +4% DM -11% EM +13% Regional Brands excl. HPC +10% DM +5% EM +13%

  56. Slide 56: Commercial Pharma | Internal Organic Sales Growth Measure

    COMMERCIAL PHARMA | INTERNAL ORGANIC SALES GROWTH MEASURE 56 Total Commercial Pharma +15.0% Adjusted for: Anaesthetics -7.9% Thrombosis in China Divestments HPC in USA Base Organic Growth +7.1%

  57. Slide 57: Our Business Model

    OUR BUSINESS MODEL 57  20th year of unbroken NHEPS growth at half year − Intention to sustain into H2 2018  Aspen has settled acquisitions made − Transformative period with focus on organic synergies  Grow established brands − Investment − Optimise supply chain − Line extensions/delivery forms −

  58. Slide 58: Our Business Model (Continued)

    OUR BUSINESS MODEL (CONTINUED) 58  Aspen has a simple commercial business model − Albeit operationally complex  Providing quality medicine − Affordably − Sustainability assured  Relevant and resilient to future healthcare pressures − Strong cash flow  De-risked relative to multinational and gene

  59. Slide 59: Prospects for H2 2018

    PROSPECTS FOR H2 2018 59  Sales performance  Anaesthetics supply constraints − Target H2 ≥ H1 in CER  Currency − Both Focus & Regional Brands VS ZAR EURO* USD**  Improved margins maintained H2 2017 14.43 13.28  Cash flow stronger in H2 2018 H1 2018 15.77 13.41 − Targeting 100% conversion for fu

  60. Slide 60: Our Purpose

    OUR PURPOSE 60  Aspen has a real purpose − Touch patients’ lives globally  Every second of every day  24 hours a day  365 days a year  To patients in need across the globe  We provide over − 12 anaesthetics/sterile products; and − 500 tablets/capsules Life is like a bicycle  This is our real

  61. Slide 61: Thank you

    © aspen Thank you

  62. Slide 62: Disclaimers

    DISCLAIMERS 62 BASIS OF PREPARATION – ROUNDING OF NUMBERS The financial results in this presentation have been rounded and disclosed in R‘millions whereas the published unaudited interim financial results have been rounded and disclosed in R ’billions. Consequently there may be rounding differences

  63. Slide 63: Appendices

    Hot DING Ss Appendices

  64. Slide 64: Appendices

    APPENDICES 64 Appendix 1: Abridged Group statement of comprehensive income Appendix 2: Group statement of financial position Appendix 3: Extract from Group statement of cash flows Appendix 4: Key currency movements vs ZAR - H1 2018 vs H1 2017 Appendix 5: Institutional investors Appendix 6: Group rev

  65. Slide 65: Appendix 1: Abridged Group Statement of Comprehensive Income

    APPENDIX 1: ABRIDGED GROUP STATEMENT OF COMPREHENSIVE INCOME 65 R’million H1 2018 H1 2017 % change Net revenue 21,924 19,822 11% Cost of Sales (10 747) (10 259) 5% Gross profit 11 178 9 563 17% Gross profit margin 51% 48% Net other operating expenses (339) (106) 221% Net operating expenses (5 674) (

  66. Slide 66: Appendix 2: Group Statement of Financial Position

    APPENDIX 2: GROUP STATEMENT OF FINANCIAL POSITION 66 R'million H1 2018 H1 2017 TOTAL ASSETS Non-current assets 86 351 71 814 Intangible assets 67 326 53 610 Property, plant and equipment 10 105 9 654 Goodwill 6 003 5 716 Deferred tax assets 1 017 1 042 Contingent environmental indemnification assets

  67. Slide 67: Appendix 2: Group Statement of Financial Position (Continued)

    APPENDIX 2: GROUP STATEMENT OF FINANCIAL POSITION (CONTINUED) 67 R‘million H1 2018 H1 2017 EQUITY AND LIABILIITIES Share capital and reserves 44 337 39 590 Non-current liabilities 37 811 44 003 Borrowings 29 579 35 585 Other non-current liabilities 2 984 3 334 Unfavourable and onerous contracts 1 47

  68. Slide 68: Appendix 3: Extract from Group Statement of Cash Flows

    APPENDIX 3: EXTRACT FROM GROUP STATEMENT OF CASH FLOWS 68 R'million H1 2018 H1 2017 Cash operating profit 6 145 5 496 Changes in working capital (1 523) (691) Cash generated from operations 4 622 4 805 Net finance costs paid (607) (915) Tax paid (1 013) (658) Cash generated from operating activities

  69. Slide 69: Appendix 4: Key Currency Movements vs ZAR

    APPENDIX 4: KEY CURRENCY MOVEMENTS VS ZAR – H1 2018 VS H1 2017 69 17.67 GBP 17.75 0% 15.77 EUR 15.25 +3% 13.41 USD 13.94 -4% 10.45 AUD 10.46 0% 4.15 BRL 4.27 -3% 3.71 PLN 3.5 +6% 2.02 CNY 2.06 -2% H1 2018 Average rate 0.72 MXN 0.72 +1% H1 2017 Average rate 0.23 RUB 0.22 +5% 0.12 JPY 0.13 -8%

  70. Slide 70: Appendix 5: Institutional Investors

    APPENDIX 5: INSTITUTIONAL INVESTORS 70 Asia Pacific ROW 4% 5% Europe 3% UK 6% North America 18% South Africa 64% As at 29 December 2017

  71. Slide 71: Appendix 6: Group Revenue by Region

    APPENDIX 6: GROUP REVENUE BY REGION 71 R’million H1 2018 H1 2017 % change H1 2017 % change (CER)* Developed Europe 6 295 5 592 13% 5 763 9% Asia Pacific 6 297 5 237 20% 5 088 24% Sub Saharan Africa 5 030 4 602 9% 4 570 10% Latin America 2 179 1 945 12% 1 925 13% Developing Europe and CIS 1 413 1 153

  72. Slide 72: Appendix 7: Merck & Co

    APPENDIX 7: MERCK & CO 72 Source: Merck Full year and fourth quarter 2017 results press release

  73. Slide 73: Appendix 7: Mylan

    APPENDIX 7: MYLAN 73 Source: Mylan Full year and fourth quarter 2017 results presentation

  74. Slide 74: Appendix 7: Hikma

    APPENDIX 7: HIKMA 74 Source: Hikma H1 2017 results press release

  75. Slide 75: Appendix 7: Allergan

    APPENDIX 7: ALLERGAN 75 Source: Allergan Full year and fourth quarter 2017 results presentation

  76. Slide 76: Appendix 7: GSK

    APPENDIX 7: GSK 76 Source: GSK Full year and fourth quarter 2017 results press release

Aspen Pharmacare Holdings — H1 2018 Earnings Presentation on 6ix